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Resistance to radiation-leukemia virus-induced leukemia is mediated by gene(s) in 
the H-2D region of the major murine histocompatibifity complex (1). The mechanisms 
by which gene(s) in this region affect leukemogenesis are hitherto unknown. However, 
previous  observations  (2)  suggest  a  role  in  disease  resistance  for  changes  in  H-2 
expression occurring immediately after virus inoculation. For example, gene products 
(antigens)  of the  H-2D  region  show  the  most  marked  and  prolonged  changes  in 
expression after virus inoculation. In addition, elevated H-2D antigen expression after 
virus inoculation occurs for thymocytes of resistant but not susceptible mice. Further- 
more,  there  is  an  inverse relation between  expression of H-2D  and  viral  antigens. 
Viral  antigen  expression  is  greater  in  susceptible  animals,  whereas  H-2D  antigen 
expression is maximal for virus-infected resistant mice. Finally, H-2 antigens usually 
disappear from the surface of radiation-induced leukemia virus (RadLV) l transformed 
cultures when overt leukemia develops. Thus, resistance to the disease is associated 
with increased H-2 antigenic expression, and the onset of leukemia is associated with 
disappearance of these antigens. 
Several  mechanisms  by  which  changes  in  H-2  antigen  expression  may  overtlv 
influence the course of the disease have been previously suggested (2).  Although the 
effect of increased H-2 expression on the other steps required for oncogenesis remains 
to be evaluated, the observations reported herein suggest  that  elevated H-2 antigen 
expression enhances the effectiveness of the host's immune responses to virus-int?cted 
cells and may function in resistance to leukemogenesis. 
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Materials and Methods 
Mice.  All animals used in the present study were bred either at Stanford University School 
of Medicine or at New York University Medical Center from animals derived from the Stanford 
colony, and generously provided by Dr. Hugh O. McDevitt. 
Virus.  Initial virus extract  (RadLV)  was derived from virus-induced lymphoid tumors of 
C57BL/Ka mice as previously described (3). This virus has been passaged independently for  1 
yr.  It is highly leukemogenic in vivo, exhibits the same host  restrictions (H-2 control) as the 
original RadLV  prepared  from C57BL/Ka lymphoid tumors, and shows  the  same sodium 
dodecyl sulfate polyacrylamide gel electrophoresis polypeptide pattern (D.  Meruelo, unpub- 
lished observations). 
H-2 Antisera.  H-2 alloantisera 056  ((B10.BR  X  A.SW) F1  anti-B10.S(7R) (anti-H-2Da)), 
and 020 ((A.TH anti-A.SW) (anti-H-2DS)) were generously provided by Dr. Hugh O. McDevitt. 
Antiserum D-30  ((B10.A  X  LP.RIII) FI, anti-Bl0.AKM) (anti-H-2Dq)) and D-llb ((A.SW 
X B10) F1 anti-DA/Sn (anti-H-2Kqlq)) were kindly provided by Dr. John G. Ray, Jr., Research 
Resources Branch, National Institutes of Health, Bethesda, Md. 
Virus Inoculation.  Under anesthesia, 0.05  ml of the virus preparation was  inoculated into 
each lobe of the thymus of 3- to 6-wk-old mice. 
Absorption Studies.  The  expression of H-2D  and  H-2K antigens in normal and  RadLV- 
infected thymocytes was  determined as previously described (2)  by measuring the ability of 
these cells to absorb appropriate alloantisera. 
asS-Methionine Labeling of Lymphocytes and One-Dimensional Sodium Dodecyl-Sulfate-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) Analyses.  Animals were killed by cervical dislocation and their 
spleens, or solid tumors growing intraperitoneally excised  and placed in phosphate-buffered 
saline (PBS).  Single cell suspensions were  prepared by gentle teasing and pipetting. Labeling 
with 35S-methionine and extraction with 0.5% NP-40 was done as previously described (4). The 
cell lysate was then centrifuged at  100,000 g for  1 h. The supernate was aliquoted and stored 
at -70°C until further use. For immunoprecipitation portions from 5 ×  106 cells were cleared 
of labeled immunoglobulins with  goat  anti-mouse Ig  (GAMIG) and carrier normal mouse 
serum (NMS) at equivalence. The resulting precipitate was removed by centrifugation at 8,000 
rpm for 20 min. The supernate was then incubated at 37°C for 30 min with specific or control 
antiserum. GAMIG was then added again and the samples incubated at 4°C overnight. The 
precipitate was then collected by centrifugation at 8,000 rpm for 20 min, washed at least  four 
times in 1% Triton-X-100-1% deoxycholate in PBS, pH 7.4, dried, and then subjected to SDS- 
PAGE according to the method of Witte and Weissman (5). 
Cultures.  All RadLV-transformed tissue culture lines were adapted from RadLV infected, 
leukemic animals. Lymphoid tissues were removed and placed in culture at a concentration of 
2-4 X  106 cells/ml. Cultures were split and fed after 2 d. Afterwards, daily observations of the 
cultures were carried out to feed  the cells as required while always keeping a  portion of the 
conditioned growth media present. The first signs of successful adaptation of the cultures was 
the formation of an epithelial sheet with clusters of round cells throughout. After several weeks, 
the latter cells became autonomous and the feeder-layer unnecessary. Success rates in adapting 
lymphoid tumors and culture varied between 30 and 60'7~. 
BW5147 cells were originally obtained from the Salk Institute, San Diego,  Calif. and have 
been maintained independently since 1975. Their karyotype and growth conditions have been 
described previously (6). 
Preparation of Effector Cells, '~Cr-Labeled Target Cells, and Assqy  for CeU-Mediated C~totoxicity.  Cells 
were  prepared and cell-mediated lympholysis activity measured as  previously described (6), 
except that cells used for this test were grown in RPMI-1640 with 25 mM Hepes (Grand Island 
Biological  Co., Grand Island, N.  Y.). The assay  was also carried out in RPMI-1640. Special 
care was given to the use of fresh Na '~lCr (Amersham Corp., Arlington Heights, Ill.) for labeling 
target cells. Incubation times varied from 4 to  12 h. 
Antiserum and Complement-Mediated Cytotoxicity.  Spleen cells were prepared with gentle teasing 
in Dulbecco's modified Eagle's medium (DMEM)  and 5~7~ FCS,  centrifuged, counted, and 
aliquoted in  tubes at  a  concentration of 20  ×  10~/tube.  They were  then centrifuged and 
resuspended in 1 ml of 1/5 dilution of the appropriate antiserum or control serum (diluted in 900  H-2 ANTIGEN  EXPRESSION  AFFECTS  RESISTANCE  TO  LEUKEMIA 
DMEM  +  5%  fetal  calf serum  [FCS]).  After 30  rain at  room temperature,  they were spun 
down, and resuspended in 3 ml of 1/9 dilution (diluted in DMEM) of agarose-adsorbed rabbit 
complement. After 45 min incubation at 37°C, cells were pooled (if more than one tube of 20 
x  106 cells was treated with a given serum), counted to assess percent cytotoxicity, centrifuged, 
washed three times,  and recounted. 
Results 
Resistance  to  Syngeneic RadLV  Tumor  Cells  Mimics  H-2D  Control of RadLV-Induced 
Neoplasm.  It  has  been  previously shown  (19)  that  if RadLV  infected,  transformed 
lymphocytes (B10.S)  are injected into  (B10.S  ×  B10.G)  F1  (susceptible  to the virus) 
or (B10.S  X  B10.S(7R))  F1  (resistant)  mice, the latter survive much longer than the 
former.  Likewise  (B10.G  ×  B10.S)  (susceptible)  F1  mice survive a  shorter time after 
inoculation  of B10.G  RadLV-transformed  cells  than  do  (B10.G  X  B10.T(6R))  F1 
(resistant)  animals.  In this  sense,  the observed resistance  to tumor cells  is consistent 
with the known observations about H-2D control of RadLV-induced neoplasia. 
Initial attempts to demonstrate cell-mediated immunity (CMI) against the injected 
B 10.S and B 10.G tumor cells failed, even in the hybrids surviving the tumor challenge. 
H-2-Negative,  RadL V Transformed Cells, Re-Express H-2 Antigens after In Vivo Growth.  It 
has been shown by absorption analysis that  RadLV-induced  tumor cells adapted  to 
culture,  appear  to show no detectable  expression  of H-2 antigens  (2).  Because  H-2 
antigens  seem  to be  required  for cell-mediated  killing  (7-9),  difficulties  with  the  in 
vitro assay for CMI may have resulted from the use of tissue culture adapted RadLV 
transformed  cells  as targets.  Therefore,  an attempt  was made  to determine  whether 
H-2 modulation  occurred if these  cells  were  grown  in  vivo in  normal,  nonleukemic 
animals. 
When syngeneic RadLV transformed cells are injected intraperitoneally  into resist- 
ant  and  susceptible  animals,  they  do  not  grow  as  an  ascites  tumor.  In  susceptible 
mice,  tumor cells  initially  invade  the  spleen  and  then  multiply  in  other  lymphatic 
organs.  However,  in  resistant  mice  tumor  cells  grow  in  the  spleen  and  lymphatic 
organs to a  lesser extent  and predominantly as a  solid peritoneal  tumor. Tumor cells 
multiply  slower  in  resistant  than  in  susceptible  mice,  and  are  often  completely 
eliminated  after some initial  growth in the former animals. 
Fig.  1 shows the results obtained when 5  x  10  e RadLV transformed,  tissue culture 
grown B10.G cells were injected  intraperitoneally  into  (B10.G  X  B10.S)  F1  (suscep- 
tible)  and  (B10.G  ×  B10.S(7R))  FI  (resistant)  mice and spleens of three to four mice 
of each type removed at various intervals to measure H-2 antigen re-expression on the 
injected  cells.  (B10.G  ×  B10.S)  F1  spleen  cells  were  incubated  with  anti-D 8 serum 
and complement and (B 10.G  X  B 10.S(7R))  F1 spleen cells were incubated with anti- 
D d serum.  Because the tumor cells were O q positive, neither serum should react with 
the growing cells, and only host cells should be lysed by the antiserum  plus comple- 
ment  treatment.  However,  treatment  of  (B10.G  ×  B10.S)  FI  and  (BI0.G  × 
B10.S(7R))  F1  spleen  cells with anti-D q serum plus complement should lyse  100%  of 
the  cells,  because  all  host  cells  and  tumor cells  should  be  killed  (provided  that  the 
tumor cells reexpress  H-2Dq).  It can be seen that  in the case of (B10.G  ×  BI0.S)  F1 
cells,  anti-D "~ serum kills  95% of the cells on day 0, but  kills  fewer and  fewer cells on 
subsequent  days, as the injected tumor cells multiply in the spleen.  Killing by anti-D q 
sera on the other hand, starts out at  96% on day 0 and declines  initially at  the same DANIEL MERUELO  901 
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FIG.  1.  Re-expression  of H-2-negative, RadLV  transformed tumor cells after in  vivo growth. 
Details provided in text. 
rate as killing by anti-D  s, but begins to kill a  larger percentage of the cells after day 
9. The same pattern can be observed in (B10.G  ×  B10.S(7R))  F1  mice. However, the 
percentage of spleen cells of these mice that can be killed with anti-D  q after day 9 is 
much higher than the percentage of spleen cells that can be killed with this serum for 
(B10.G  X  B10.S)  F1  mice. 
These findings strongly suggest  that  phenotypically H-2-negative tumor cells can 
proliferate  in  vivo  to  give  rise  to  tumor  cells  which  express  the  appropriate  H-2 
antigens. However, the above experimental procedures involve simultaneous compar- 
ison of killing by several antisera; and is less desirable than more direct measurements. 
Fortunately,  RadLV  transformed  cells  often  grow  as  solid  peritoneal  tumors  in 
resistant mice. These tumors are composed almost entirely of donor cells and few host 
cells. Because little contamination, if any, by host cells is encountered, direct assay of 
H-2  re-expression  can  be  carried  out  on  the  growing  tumor  cells.  By  use  of two 
additional  techniques,  it has been possible to demonstrate directly that  H-2 antigen 
re-expression occurs for cells derived  from the injected cells, as they multiply in  the 
peritoneal cavity. For example, when a  fixed number of tumor cells is recovered and 
tested at various intervals after inoculation,  their anti-H-2 absorbing capacity grad- 
ually  increases  (data  not  shown).  Likewise,  the  ability  of these  cells  to  bind  H-2 
antibodies, as detected by a  two-step radioimmunoassay, markedly increases as their 
exposure to the in vivo environment lengthens  (data not shown). 
As a  further check, the re-expressed antigens were compared by SDS-PAGE with 
normal spleen cellular H-2 antigens.  Spleen cells, tissue culture adapted B 10.T(6R), 
and in vivo grown B 10.T(6R) cells from a solid peritoneal tumor were incubated with 
35S-methionine  for 3  h.  After  this  step,  immunoprecipitation  of NP-40  lysates was 
done with  H-2 alloantisera and goat anti-mouse IgG, and the resulting precipitates 
were  submitted  to  SDS-PAGE  analysis  and  compared  with  one  another  (Fig.  2). 
Panel A  shows an important  fact. RadLV transformed tumor cells growing in vitro 902  tt-2  ANTIGEN EXPRESSION  AFFECTS RESISTANCE TO  I.EUKEMIA 
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Fxc.  2.  Synthesis and expression of ft-2 antigens on spleen, and both in vivo and in vitro grown, 
RadLV transformed  [Yml~hucytes. A: in vitro grown BI0.T(6R); B: in vivo grown B10.T(6R):  C: 
normal B 10.T(6R) spleen cells. (',ells ,,','ere incubated in I)MEM for 3 h with :~SS-methionine.  After 
this step,  inmmnoprecipitation of NP-4ll tysates were done with 11-2 alhmntisera and g,  oal anti+ 
mouse lgG, and the resulting precipitate sul)mitted  to SI)S-PAGE analysis. 
not only fail to express  H-2  antigens as detected  by absorption analysis (2), but also 
cannot be shown to synthesize these antigens by the present scheme. It is possible that 
synthesis of these antigens does occur, yet  degradation  takes place immediately after 
the nascent polypeptide chains are formed,  yielding no detectable  product, or that  a 
nonantigenic polypeptide  precursor  is  formed  and  remains uncleaved.  Panel  C  is  a 
control spleen preparation.  Tile usual 45,000  and  12,000  tool  wt  pattern,  associated 
with  H-2  antigens  and  tile  mouse  analogue  of  fi2  microglobulin,  respectively,  is 
obtained.  Transformed  BI0.T(6R)  tumor  cells  growing  in  vivo  (panel  B)  show  a 
similar pattern as the spleen cells ahhough  the amount  of material precipitated  from 
comparable cellular extracts  appears  to be smaller. DANIEL  MERUELO  903 
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RadLV transformed cells can be detected only bv  F~c.  3.  Cell-mediated cytotoxic activity against 
using tt-2a-positive, virus-positive, target cells. I  ×  10" spleen cells from BI0.T(6R) mice injectect 
12-18 d previously with RadLV transformed BI0.T(6R)  cells were incubated  with '~lCr-labeled 
cells grown in vitro; passaged in vivo for l0 d; BW5147, or normal BI0.T(6R) spleen cells. 6 or 14 
h later, the percent-specific '~]Cr  release was measured to indicate CMI activity. 
CMI Activity against RadL V Transformed Cells Can Be Detected Only by Using H-2-Positive 
Target Cells.  That  antigen  re-expression  is important  in  the effectiveness  and  dem- 
onstration  of CMI immunity is apparent  from Fig.  3.  When  1.25  X  l0  s spleen  cells 
from resistant  animals,  injected  12-18 d  before,  are  incubated  with  the same  tissue 
culture  grown  cells  (5  ×  104) as  they  were  inoculated  with,  no  CMI  activity  is 
detectable.  On the other hand,  when these same spleen cells are incubated with 5  X 
104 RadLV tumor cells grown in vivo for 10 d, CMI activity is clearly demonstrable. 
The  CMI  response  appears  to be specific  because  neither  BW5147  cells  (H-2 k)  nor 
normal spleen  cells  (H-2  a)  are lysed by the effector cells.  They also fail to lyse EL-4 
(H-2Db), which were derived  from a  C57BL/6 mouse (data not shown). 
A technically more difficult experiment is shown in Fig. 4. Here tumor cells growing 
in  the spleen  of hybrid  animals  injected  for  10  d  are  recovered after  elimination  of 
normal cells with antiserum  to the parental  H-2 haplotype opposite to that expressed 
by the  tumor plus  complement.  The  recovered cells  are  then  labeled  with  '~lCr  and 
used as targets for killer cells derived from hybrid mice, injected  12-18 d  before with 
tumor cells.  Panel  A  shows incubation  of (B10.G  ×  B10.S(7R))  F1  (resistant)  killer 
cells  with  in  vivo and  in  vitro  grown  B10.G  cells  and  panel  B  incubation  of these 
same  targets  with  killer  cells  derived  from  (B10.G  ×  B10.S)  F1  (susceptible)  mice 
injected  12-18 d  previously with  B10.G  tumor cells.  In addition  to demonstrating  a 
requirement  for  H-2  antigens  to  obtain  killer  cell  activity,  the  results  show  that 
resistant  mice develop effective killer cells to a  tumor challenge to which susceptible 
mice are not capable of responding effectively. 
Resistant Mice Develop Greater Numbers of Effector Cells When Inoculated with RadL V Than 
Do  Susceptible  Mice.  At  various  intervals  3-6  wk  of age  BI0.G  (susceptible)  and 904  H-2  ANTIGEN  EXPRESSION  AFFECTS  RESISTANCE  TO  LEUKEMIA 
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Fie.  4.  Resistant mice develop effective killer cells to a tumor challenge to which susceptible mice 
are not capable of responding effectively. RadLV transformed cells growing in vivo; recovered after 
10 d of passage by elimination of normal spleen cells with antiserum plus complement, or growing 
in vitro were labeled with 51Cr and used as targets for killer cells derived from hybrid mice injected 
12-18 d previously with tumor cells. A: CMI activity of (B10.G X B10.S(7R)) FI mice (resistant); 
B: CMI activity of (BI0.G  X  B10.S) FI mice (susceptible);  X, in vivo grown cells; ~, in vitro 
grown cells. 
B10.T(6R)  (resistant)  mice  were  inoculated  intrathymically  with  RadLV.  Mice 
injected at different times were then assayed simultaneously for CMI.  i0 d  before the 
test  for CMI,  (BI0.G  ×  B10.S)  F1  mice were injected with  B10LG  tumor cells, and 
(B10.G  X  B10.T(6R))  F1  mice  with  B10.T(6R)  tumor  cells.  On  the  day  of assay 
spleens and lymph nodes were harvested from  all virus injected mice and  used  as a 
source  of  effector  cells.  Spleen  cells  from  (B10.G  ×  B10.S)  F1  and  (B10.G  X 
B 10.T(6R)) F 1 mice were removed, treated with anti-D  s and anti-D  q plus complement, 
respectively;  labeled with  5~Cr  and  used  as  a  source  of target  cells  to  assay  CMI 
activity. The  results of this experiment are shown  on  Fig. 5.  CMI  activity could be 
detected in  resistant  and  not  susceptible mice at  an  effector to target  ratio of 25:1, 
although some effectors could be detected in susceptible mice at a ratio of 100:1  (data 
not shown). If instead tumor cells grown in vitro were used as target cells (from either 
B 10.G or B 10.T(6R)), no detectable killing could be seen with effectors from resistant 
or susceptible mice. 
RadL V Infected Thymocytes  from Resistant Mice Can Elicit Strong CML Responsiveness When 
Used to Challenge Normal F1  Mice,  The  results so  far suggest  that  H-2  antigens  are 
required for successful killing of target cells, because in vitro grown H-2-negative cells 
are not  lysed. In addition, viral antigens are required because normal,  H-2-positive 
spleen cells do not serve as targets. But  none of these studies demonstrates that virus 
infected thymocytes displaying high levels of H-2 are better immunogens than normal 
thymocytes. DANIEL  MERUELO  905 
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Fro.  5.  Resistant mice develop effective CMI when inoculated with RadLV although susceptible 
mice  do  not.  Weanling  BI0.G  (susceptible)  and  BI0.T(6R)  (resistant)  mice  were  inoculated 
intrathymically with  RadLV  at  various times. These mice were then assayed simultaneously for 
CMI as described in the text. 
An  experiment designed  to test  the  latter concept is shown  in  Fig.  6.  (B10.S  X 
B10.S(7R)) F I mice were inoculated with thymocytes from B10.S (bottom panel) or 
B10.S(7R)  (top  panel)  mice  untreated,  or  previously  inoculated  with  RadLV  at 
various  intervals.  The  ensuing  CML  response  against  in  vivo  passaged  B10.S  or 
B 10.S(7R) RadLV transformed cells was then measured 12 d later. The results clearly 
indicate  that  virus  infected  thymocytes displaying  high  levels  of H-2  are  better 
immunogens than normal thymus-derived lymphocytes. 
Discussion 
The  findings  presented  in  this  report  indicate  that  the  genetics  of resistance  to 
syngeneic  RadLV-induced  tumor  cells  are  identical  to  H-2D  control  of RadLV- 
induced leukemogenesis. These findings are suggestive of a  role for H-2D gene(s)  at 
some point after malignancy has ensued. This type of resistance would be expected to 
be  immunological.  Several observations  are  in  accord with  this  expectation.  First, 
CMI against RadLV transformed or infected cells can be detected with ease when H- 
2-positive target cells are used in the cell-mediated lympholysis (CML) assay. Second, 
resistant  mice develop greater numbers of effector cells when infected with  RadLV 
than  do  susceptible  mice.  Third,  the  previous observation  that  rapid  increases  in 
cellular synthesis and cell-surface expression of H-2 antigens are detectable immedi- 
ately after virus  inoculation  has  suggested  that  altered expression of H-2 antigens 
may play a significant role in the mechanism(s) of host defense to virus infection. This 
concept is strengthened by the findings documented in  Fig.  6;  namely injection of 
normal  (uninfected) thymocytes into syngeneic recipients of resistant  or susceptible 906  tl-2  ANTIGEN  EXPRESSION  AFFECTS  RESISTANCE TO  I,EUKEMIA 
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E[~;.  6.  Only  RadLV  infected  thymocytes  from  resistant  mice elicit  CMI.  3  to  6-wk-old  mice 
(B[0.S  and  B10.S(7R))  were injected intrathymically with RadLV at  various  intervals.  At a time 
when  mice exposed  to RadI,V fi~r 3,  5,  7, and  9 wk were available, these  mice,  and  mice never 
exposed to the virus, were sacrificed. Thymuses from these mice were removed, teased, and injected 
at a concentration of 10  ×  10  ~ into (BI0.S  X  B10.S(7R))  FI mice. The top panel reflects response 
of mice injected with B 10.S(7R) thymocytes and the bottom panel responses of mice injected with 
B 10.S thymocytes.  12 d later,  the spleens of these mice were removed and tested  for the presence of 
effector  cells by a  ~tCr in  vitro cytotoxicity assay  (Materials and  Methods).  Target cells for this 
assay were obtained by passing  I  ×  10  ~ tissue culture grown  B10.S or B10.S(7R)  cells in  (B10.S 
×  B IO.S(TR)) El (|I-2D  ~/`l) mice. On the day of assay, spleens from the latter mice were removed, 
teased, and aliquots treated with antiserum against  the | t-2 of the parental type not represented  by 
the tumor plus complement. Thus,  if FI mice had  been  injected with B10.S tumor cells (|[-2D~), 
they were treated with anti-H-2D  'f plus complement and  if the F1  were injected with BI0.S(7R) 
tumor cells (H-2Dd), the spleen cells were treated with anti-D" plus complement. The ceils remaining 
after treatment with antiserum plus complement were labeled with ~Cr and used as target cells in 
the in vitro cytotoxicity assay. The specific cytotoxic responses obtained from mice challenged with 
thymus from normal (time 0) or RadLV infected  thymocytes (times 3, 5, 7, and 9) are shown by a 
bar graph.  The responses  of (BI0.S  X  BI0.S(TR))  FI  mice were  measured against  both  in  vivo 
passaged  B 10.S •  and B 10.S(7R) tumor cells ~. 
H-2 type does not stimulate  a  CML  response.  However, injection of RadLV  infected 
thymocytes  from resistant  mice produces  a  vigorous CMI  response,  and  such  thymo- 
cytes elicit the strongest response at a  time when both H-2 and viral antigen expression 
is elevated. By contrast,  injection of infected thymocytes from susceptible mice, which 
express  viral  antigens,  but  low  levels  of  H-2  antigens,  does  not  stimulate  a  CML 
reaction.  In  addition,  target  recognition  appears  to  be  specific  for  H-'2D d  antigens 
because  F1  mice challenged with  infected  B 10.S(7R)  thymocytes can  lyse B 10.S(7R) 
targets  (Dd),  but  not  B 10.S target  (D~), even after both targets  have been passaged  in 
vivo and  express  H-2 antigens. 
Preliminary experiments indicate that  transfer of thymocytes infected with RadLV 
for a  short  time  (e.g.  3  wk),  from  resistant  or susceptible  mice, into  irradiated  adult, 
syngeneic  F1  mice  leads  to  death  from  tumorigenesis  in  a  relatively  short  time  (D. 
Meruelo,  unpublished  observations).  It  is  unlikely  that  such  death  results  from  the 
induction  of leukemia  by  virus present  in  transformed  cells,  because  the progress  of 
disease  is too rapid,  and  RadLV  does  not  lead  to  leukemia when  injected  into adult DANIEL MERUEI,O  907 
mice.  The  likely conclusion  is  that  preleukemic  cells  exist  in  the  thymus  of both 
resistant  and susceptible mice and  that  transfer to the irradiated host environment 
permits such cells to escape the immunological control that  prevents their growth in 
unirradiated, resistant mice. 
It has been shown here that  the failure to detect differences in anti-RadLV CMI 
between resistant and susceptible animals was due to the absence of H-2 determinants 
on  the  target  cells  used.  A  change  in  phenotypic  expression  from  H-2  +  to  H-2- 
accompanies  overt  leukemia  and  can  be  reversed  by  in  vivo  passage  by  RadLV 
transformed cells through healthy, syngeneic recipients. H-2 antigen modulation has 
been  previously  observed  by  Boyse  et  al.  (10,  I1).  In  these  studies,  an  inverse 
relationship  was  observed  in  cells  undergoing  antigenic  modulation  between  the 
expression of TL and H-2D antigens. It has been suggested that TL antigens derived 
from a viral genome integrated in chromosome 17 (12). In this regard, two observations 
are  relevant.  First,  tissue  culture  adapted,  RadLV-transformed  cell  lines  produce 
substantial levels of thymotropic virus, and are H-2 negative, but after in vivo passage 
these  cells  show  markedly  reduced  virus  production  and  full  expression  of H-2 
antigens. In addition, it has been shown (2) that  from the early stages of the disease, 
there is an inverse relationship between viral and H-2 antigen expression. A reduction 
in  virus  production  could  be  explained  by  antibody  or  cellular  elimination  or 
reduction of RadLV.  However, there is some evidence that  11-21)  gene(s)  regulate 
virus  production  (13).  In  view of these  findings, the  notion  that  a  viral  genome is 
integrated in chromosome 17 is provocative and should be pursued further. 
The  data  presented  here  are  of  further  relevance  in  view  of two  established 
observations regarding type-C RNA  virus-induced leukemia.  First, it is well known 
that murine type-C RNA virus must be inoculated in neonatal or very young mice for 
successful leukemogenesis. Second, a great many of these viruses exhibit preferential 
tropism for the thymus. This is best exemplified by RadLV, which is usually injected 
intrathymically for optimal  leukemia  incidence, and  causes  a  disease  which  has as 
principal characteristic the development of thymomas (14). In view of the importance 
of H-2 antigens  for T-cell killing  (7-9), these two  facts could  be explained if virus 
infection of neonatal cells or thymocytes (low H-2 bearing cells)  is more successful 
than  infection of adult  or mature cells because cells having high  levels of H-2 and 
virus antigen trigger strong CMI and become rapidly eliminated. 
The very rapid and dramatic increases in expression of H-2 antigens on thymocytes 
of resistant  mice  immediately after virus  injection  may represent  an  evolutionally 
developed defense mechanism. This mechanism of defense would be expected to be of 
particular importance because it occurs in  the thymus. Zinkernagel et al.  (15)  have 
recently provided evidence that  the thymus is the site where cell-cell recognition is 
learned. 
There is one observation that cannot be completely explained by these results. This 
is the finding that  F1  mice of resistant 1t-2 type survive a  tumor inoculation longer 
than do F1  mice of susceptible H-2 genotype. Because tumor cells growing in both 
Fls appear to re-express H-2 antigens after a few days of in vivo growth, the inability 
of susceptible mice to reject the tumor cells and  the ability of resistant  mice to, at 
least, survive longer, raise the possibility that  an Ir gene importarit in resistance to 
RadLV-induced  neoplasia  may  be  operative  in  the  H-2Dregion.  If  so,  H-2 q/a 
of H-28/a  F1  mice  would  be  high  responders,  whereas  11-2 ~/~  F1  would  be  low 908  H-2 ANTIGEN EXPRESSION AFFECTS RESISTANCE TO LEUKEMIA 
responders. This observation requires additional study. 
The present studies need to be expanded to encompass other type-C RNA viruses. 
Some investigators have reported similar effects on H-2 antigen expression by Friend 
(16) and AKR viruses (17), but a more detailed study is required. If similar changes 
in  HLA  expression  at  various  stages  of  leukemogenesis  could  be  demonstrated 
(suggested by reported instances in which investigators were unable to type leukemic 
cells [18]), these findings would have very significant clinical implications. 
Summary 
Resistance to neoplasia  caused by radiation-induced leukemia  virus  (RadLV)  is 
mediated  by gene(s)  in  the  H-2D region of the  major histocompatibility complex. 
The previous observation that  rapid  increases in cellular synthesis and  cell-surface 
expression of H-2  antigens  are  detectable immediately after virus  inoculation  has 
suggested that altered expression of H-2 antigens may play a  significant role in the 
mechanism(s)  of host  defense to  virus  infection. This concept is  supported  by the 
following observations. First, cell-mediated immunity against RadLV transformed or 
infected cells can be detected with ease when H-2-positive target cells are used in the 
cell-mediated lympholysis (CML) assay. (Although RadLV transformed cells obtained 
from overtly leukemic animals  and  maintained  in  tissue culture are  H-2  negative, 
these cells can regain their H-2 phenotype by in vivo passage in normal animals. The 
H-2-negative cells are poor targets in a CML assay.) Second, resistant mice develop 
greater numbers of effectors when  infected with  RadLV than  do susceptible  mice. 
Third,  injection  of normal  (uninfected)  thymocytes  into  syngeneic  recipients  of 
resistant  or  susceptible  H-2  type  does  not  stimulate  a  CML  response.  However, 
injection of RadLV infected thymocytes from resistant mice produces a vigorous CMI 
response, and such thymocytes elicit the strongest response at a time when both H-2 
and viral antigen expression is elevated. By contrast, injection of infected thymocytes 
from susceptible mice, which express viral antigens,  but low levels of H-2 antigens, 
does not stimulate a CML reaction. 
These  findings  may  explain  the  easier  induction  of leukemia  found  by  many 
investigators when virus is inoculated into neonatal mice and the preferential thymus 
tropism of some oncogenic type-C RNA virus. Cells expressing very low levels of H-2, 
such as thymocytes, may serve as permissive targets for virus infection because they 
lack an important component (H-2 antigens) of the dual or altered recognition signal 
required to trigger a defensive host immune response. 
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